NEW YORK, March 4 - GlaxoSmithKline is evaluating Ambit Biosciences' screening technology to characterize small molecule kinase inhibitors, Ambit said today.
Since January, Ambit has been studying interactions between GSK's kinase inhibitors and proteins using its phage display-based screening approach.
Ambit Biosciences is based in